I guess they think I somehow cheated the system.” Despite huge demand for the diabetes treatment-turned-weight-loss wonder ...

The convenience and lower cost of the oral pill may be critical to some patients, which could expand the market, improve ...

Novo Nordisk’s ‘There’s Only One Ozempic’ campaign is about reasserting the drugmaker’s brand name in an increasingly ...

Learn more about GLP-1 pills and how they may be more convenient and cost-effective than the injections.

Novo Nordisk’s new Ozempic ads star Justin Long and John Hodgman, the “Mac” and “PC” of an iconic Apple campaign, to promote ...

Semaglutide’s U.S. patents keep generics out until around 2031 or 2035, maintaining Novo Nordisk’s exclusivity and high ...

It depends. There have been a few clinical trials on the impact of GLP-1 injectable medications on weight loss with different ...

The weight loss drug Wegovy is now available as a tablet in more than 70,000 U.S. pharmacies as well as select telehealth ...

Novo Nordisk’s new Wegovy pill hit the market this week. The Danish drug maker, best known for GLP-1 injections like Ozempic and Wegovy, is now the first company to manufacture and receive FDA ...

As weight loss drugs move from injections to pills, this thematic ETF provides broad exposure for investors looking to profit ...

GLP-1 medications have been a life-changing tool to help people manage their blood sugar and lose weight. But the most popular forms of these medications have a big drawback: You have to inject ...

Novo Nordisk entered 2026 with fresh momentum after the U.S. launch of its oral Wegovy pill. Is the stock a buy now?